University of Pittsburgh researchers have developed a method to enhance vasculogenic reprogramming using TNT (EFF) induced delivery of Etv2, Foxc2, and Fli1 plasmids. This method significantly increases ischemic murine skin regeneration by inducing vasculogenic fibroblasts (VF). The approach has shown promising results in both in vitro and in vivo studies, highlighting its potential to revolutionize regenerative medicine and vascular biology research.
Description
Tissue nanotransfection (TNT) is a novel technique that uses topical electrophoretic delivery to introduce specific transcription factors (Etv2, Foxc2, and Fli1) into cells. This method has been shown to induce vasculogenic fibroblasts (VF) in ischemic tissues, promoting the formation of new blood vessels. The technology leverages the upregulation of ten-eleven translocase (TET) enzymes, which play a crucial role in the vasculogenic reprogramming process. The enhanced expression of TET1/2/3 is associated with increased endothelial gene expression and improved tissue perfusion in diabetic ischemic limbs.
Applications
- Research tool
- Vascular biology studies
- Developmental biology research
- Regenerative medical research
Advantages
The TNT (EFF) delivery method significantly enhances vasculogenic reprogramming by upregulating TET enzymes, which are crucial for inducing vasculogenic fibroblasts. This approach not only increases our understanding of the role of TET enzymes in vasculogenic induction but also holds potential for improving treatments for diabetic ischemic conditions and other vascular diseases. Additionally, it offers a novel method for promoting tissue regeneration and wound healing
Invention Readiness
The technology has been validated through extensive in vitro and in vivo studies, demonstrating its efficacy in inducing vasculogenic fibroblasts and improving tissue perfusion. Prototype performance has been validated, and the method has shown significant potential in preclinical models.
